Fragmin Side Effects

Generic Name: dalteparin

Note: This page contains information about the side effects of dalteparin. Some of the dosage forms included on this document may not apply to the brand name Fragmin.

Not all side effects for Fragmin may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to dalteparin: subcutaneous injectable, subcutaneous solution

In addition to its needed effects, some unwanted effects may be caused by dalteparin (the active ingredient contained in Fragmin). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking dalteparin:

More common
  • Deep, dark purple bruise, pain, or swelling at the place of injection
Less common
  • Bleeding of gums
  • coughing up blood
  • difficulty with breathing or swallowing
  • dizziness
  • headache
  • increased menstrual flow or vaginal bleeding
  • nosebleeds
  • paralysis
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark brown urine
  • shortness of breath
  • unexplained pain, swelling, or discomfort, especially in the chest, abdomen or stomach, joints, or muscles
  • unusual bruising
  • vomiting of blood or material that looks like coffee grounds
  • weakness
  • Back pain
  • bleeding from mucous membranes
  • bluish or black discoloration, flushing, or redness of the skin
  • burning, pricking, tickling, or tingling sensation
  • coughing
  • feeling faint
  • fever
  • leg weakness
  • numbness
  • problems with bowel or bladder function
  • skin rash (which may consist of pinpoint, purple-red spots), hives, or itching
  • sloughing of the skin at place of injection
  • swelling of the eyelids, face, or lips
  • tightness in the chest or wheezing

For Healthcare Professionals

Applies to dalteparin: subcutaneous solution


Bleeding or hemorrhagic complications may occur at any site in the body. However, in general the incidence of bleeding has been low. Hematoma at the injection site is the most commonly reported bleeding complication, and the incidence of bleeding may increase with doses above 2500 intl units per day.[Ref]

Any unexplained decrease in blood pressure and/or hematocrit should prompt consideration of a possible hemorrhagic event.

Protamine may be used to neutralize the hemorrhagic effects of dalteparin. Protamine should be given in a dose of 1 mg protamine per 100 anti-Xa units of dalteparin.

A well controlled multicenter study (Kakkar et al, 1993) evaluated the prevention of venous thromboembolism after major abdominal surgery. The total number of patients with major bleeding episodes was not significantly different (3.6% versus 4.8%, p=0.10) with dalteparin 2500 intl units once a day versus 5000 intl units unfractionated heparin twice a day. However, the incidence of wound related hematomas was significantly greater in the heparin group (1.4% versus 2.7%).

In another study (Bergqvist et al, 1986) 5000 intl units of dalteparin once a day compared to 5000 intl units of unfractionated heparin two times a day led to significantly more hemorrhagic complications (4.6% versus 11.6%). There was no difference in the reduction of deep vein thrombosis between the two treatment groups. The higher dosage of dalteparin may have led to more bleeding problems.

The manufacturer states in the dalteparin package labeling that the incidence of bleeding may increase with higher doses. The number of postoperational transfusions required in patients receiving 2500 intl units versus 5000 intl units per day was 5.7% (n=459) and 15.9% (n=508) of patients, respectively.

Kakkar and colleagues noted that compared to non-bleeders, patients who bleed with the use of dalteparin were older (mean age 64 years), more likely to be male, to have a malignancy, or to be taking nonsteroidal anti-inflammatory agents, including aspirin.[Ref]


Hematologic side effects have included thrombocytopenia (up to 13.6%), thrombocytosis, thrombosis, and hypochromic anemia. Thrombocytopenia has occurred more frequently in patients treated with unfractionated heparin than with low molecular weight heparin. The manufacturer reports platelet counts of less than 100,000/mm3 and less than 50,000/mm3 in less than 1% of dalteparin-treated patients from initial clinical trials supporting non-cancer indications. The true incidence of dalteparin-induced thrombocytopenia is not known.

Hematologic side effects have also included a case of hematoma with subsequent compartment syndrome in the thigh of a patient receiving dalteparin (the active ingredient contained in Fragmin) for angina.

Patients undergoing spinal/epidural anesthesia or puncture and anticoagulation or who are scheduled to be anticoagulated with low molecular weight heparins or heparinoids are at risk for long-term or permanent paralysis due to epidural or spinal hematoma. The risk of these events is increased by the use of indwelling epidural catheters or by concomitant use of platelet inhibitors, other anticoagulants, or drugs that affect hemostasis.[Ref]

A well-controlled clinical trial (Warkentin, et al) evaluated the frequency of heparin-induced thrombocytopenia in 665 patients receiving a low molecular weight heparin or unfractionated heparin for postsurgical prophylaxis of deep vein thrombosis. Heparin-induced thrombocytopenia was defined as a decrease in platelet count below 150,000 m2 that began 5 or more days after the start of the study drug and a positive in vitro test for antibodies. Heparin-induced thrombocytopenia occurred in 2.7% of patients receiving low molecular weight heparin. The incidence of thrombosis was significantly higher in those patients with heparin-induced thrombocytopenia (88.9% versus 17.8%). Heparin-dependent IgG antibodies occurred more frequently in those receiving unfractionated heparin versus low molecular weight heparin (7.8% versus 2.2%, respectively).

One small study (Ramakrishan, et al) reported that the incidence of cross-reactivity between unfractionated heparin and dalteparin in patients with heparin-induced thrombocytopenia was 40% (6/15 patients). Seven of the remaining 9 patients who did not demonstrate in vitro cross reactivity were successfully treated with dalteparin. Due to the extensive cross-reactivity, low molecular weight heparins are not indicated for treatment of heparin-induced thrombocytopenia. However, many studies have shown this can be done successfully.

Patients previously exposed to unfractionated heparin or a low-molecular-weight heparin appear to be more susceptible to developing heparin-induced thrombocytopenia (HIT) and HIT-related thromboembolic complications (e.g., transient ischemic attack, stroke) than those who were never exposed.

Heparin-induced thrombocytopenia (HIT) is an immune-mediated, prothrombotic reaction that occurs in 0.5% to 5% of patients treated with unfractionated heparin and in less than 1% of patients treated with a low molecular weight heparin (LMWH). The decrease in platelet count associated with HIT usually begins 5 to 14 days after starting heparin. However, patients with a previous exposure to heparin may have an abrupt decrease in platelets upon restarting heparin. Patients with LMWH-induced HIT exhibit a longer delay in the onset of symptoms compared with those who develop it from unfractionated heparin. Following discontinuation, platelet counts begin to recover within 4 days, but may take more than 2 weeks in patients with high-titer HIT antibodies. Thrombocytopenia is caused by heparin-dependent IgG antibodies that bind to a specific platelet protein, platelet factor 4 (PF4). The heparin-PF4-IgG immune complex binds to platelets causing platelet activation. The activated platelets cause release of platelet-derived procoagulant microparticles, which accelerate coagulation reactions and generates thrombin. LMWHs have a high cross-reactivity with circulating heparin-PF4-IgG immune complex. Factors associated with a higher risk for developing HIT-associated thrombosis include women, nonwhites, severity of thrombocytopenia, and lower body weight. Complications associated with HIT include exacerbation of venous thromboembolism, arterial or venous thrombosis, limb gangrene, stroke, and skin necrosis. The antibodies that cause HIT will usually disappear after approximately 3 months; therefore, use of unfractionated heparin or LMWH may be considered in a patient with a history of HIT if the antibody test is negative.[Ref]


Albada and colleagues noted increases in serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) from 17 units/L to 24.5 units/L and 22.5 units/L to 45 units/L, respectively, in those receiving dalteparin (the active ingredient contained in Fragmin) up to 10 days for treatment of acute venous thromboembolism. Liver functions tests tend to reach a maximum within the first week of therapy and then usually return to normal.

The manufacturer has reported asymptomatic increases in hepatic transaminase levels (SGOT/AST and SGPT/ALT) greater than 3 times the upper limit of normal in 4.7% and 4.2%, respectively, of patients with non-cancer indications.[Ref]

Hepatic side effects of dalteparin and other low molecular weight heparins have included asymptomatic transient elevations in liver function tests that usually are reversible and clinically insignificant.[Ref]


Local side effects of subcutaneous injections include pain, erythema, and hematoma formation. Rarely patients may experience painful, red induration and necrotic ulcerations at the injection site. Skin necrosis distant from the injection site has also been reported.[Ref]

The most commonly reported side effect is hematoma at the injection site. Pain at the injection site may be dose-related, occurring more frequently with doses above 2500 intl units per day. One study found that pain at the injection site was significantly greater with unfractionated heparin (5000 intl units two times a day) versus dalteparin (5000 intl units once a day).

Skin necrosis has occurred with low molecular weight heparin and may be due to toxic epidermal necrolysis.[Ref]


Hypersensitivity side effects have rarely included rash, fever, pruritus, bullous eruption and skin necrosis. Anaphylactic reactions have been reported.[Ref]


A patient suffered severe osteoporosis after using high dose unfractionated heparin for one year for recurrent deep vein thrombosis and pulmonary embolism. The patient was switched to 15,000 units of low molecular weight heparin daily and remained free from thromboembolism or osteoporosis. This uncontrolled, preliminary report suggests low molecular weight heparins may not cause osteoporosis.[Ref]

Musculoskeletal side effects have included a case report suggesting that low molecular weight heparins may prevent osteoporosis during prolonged use. Unfractionated heparin may aggravate or cause osteoporosis.[Ref]


Dermatologic side effects have included alopecia and rare cases of skin necrosis. At least one case of acute generalized exanthematous pustulosis has been reported after administration of dalteparin (the active ingredient contained in Fragmin) Following discontinuation, symptoms resolved within 2 weeks.[Ref]

Alopecia related to the use of dalteparin has been reported. Cases have involved female patients ranging in age from 9 years to 75 years. The 9 year old patient required anticoagulation for a cardiac disease while the other patients were anticoagulated during dialysis for chronic renal failure. In each case, the withdrawal of dalteparin resulted in a return to normal hair growth.[Ref]


Genitourinary side effects including at least one case of priapism associated with dalteparin (the active ingredient contained in Fragmin) therapy have been reported.[Ref]


1. Cziraky MJ, Spindler SA "Low-molecular-weight heparins for the treatment of deep-vein thrombosis." Clin Pharm 12 (1993): 892-9

2. Dunn CJ, Sorkin EM "Dalteparin sodium: a review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders." Drugs 52 (1996): 276-305

3. Bratt G, Tornebohm E, Lockner D, Bergstrom K "A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment." Thromb Haemost 53 (1985): 208-11

4. Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S "Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group." Lancet 341 (1993): 259-65

5. "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn, Kalamazoo, MI.

6. Kakkar VV, Kakkar S, Sanderson RM, Peers CE "Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism." Haemostasis 16 Suppl 2 (1986): 19-24

7. Ockelford PA, Patterson J, Johns AS "A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin)." Thromb Haemost 62 (1989): 1046-9

8. Bergqvist D, Burmark US, Frisell J, et al. "Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin." Semin Thromb Hemost 16 Suppl) (1990): 19-24

9. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin." N Engl J Med 332 (1995): 1330-5

10. Ramakrishna R, Manoharan A, Kwan YL, Kyle PW "Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (fragmin) and heparinoid, danaparoid (orgaran)." Br J Haematol 91 (1995): 736-8

11. Hartl P, Brucke P, Dienstl E, Vinazzer H "Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin." Thromb Res 57 (1990): 577-84

12. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis 16 Suppl 2 (1986): 11-8

13. Sugiyama T, Itoh M, Ohtawa M, Natsuga T "Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics." Thromb Res 68 (1992): 119-29

14. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F "Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial." Am J Cardiol 82 (1998): l19-24

15. Arepally GM, Ortel TL "Clinical practice. Heparin-induced thrombocytopenia." N Engl J Med 355 (2006): 809-17

16. Burnett B, Bracket E, Larsen J, et al "Health care guideline: deep vein thrombosis (DVT) diagnosis algorithm. Available from: URL:" ([2006 Feb]):

17. Menajovsky LB "Heparin-induced thrombocytopenia: clinical manifestations and management strategies." Am J Med 118(Suppl 8A) (2005): 21-30

18. Howard PA "Dalteparin: a low-molecular-weight heparin." Ann Pharmacother 31 (1997): 192-203

19. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F "Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia." Chest 129 (2006): 1407-16

20. Lassen MR, Borris LC, Anderson BS, Jensen HP, Bro HPS, Andersen G, Petersen AO, Siem P, Horlyck E, Jensen BV, Thomsen PB "Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish prolonged prophylaxis (DaPP) study." Thromb Res 89 (1998): 281-7

21. Kontny F, Dale J, Abildgaard U, Pedersen TR "Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arteria embolism after acute anterior myocardial infarction: the Fragmin i Acute Myocardial Infarction (FRAMI) Study." J Am Coll Cardiol 30 (1997): 962-9

22. Rizzieri DA, Wong WM, Gockerman JP "Thrombocytosis associated with low-molecular-weight heparin." Ann Intern Med 125 (1996): 157

23. Levine RL, McCollum D, Hursting MJ "How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?" Chest 130 (2006): 681-7

24. Martineau P, Tawil N "Low-molecular-weight heparins in the treatment of deep-vein thrombosis." Ann Pharmacother 32 (1998): 588-98,601

25. Das P, Ziada K, Steinhubl SR, et al. "Heparin-induced thrombocytopenia and cardiovascular diseases." Am Heart J 152 (2006): 19-26

26. Eichinger S, Kyrle PA, Brenner B, Wagner B, Kapiotis S, Lechner K, Korninger HC "Thrombocytopenia associated with low-molecular-weight heparin" Lancet 337 (1991): 1425-6

27. Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Soderberg K "Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis." Thromb Haemost 76 (1996): 195-9

28. Marymont JH, Murphy GS, Gilbert HC "Intraoperative heparin and heparin-induced thrombocytopenia." Anesth Analg 102 (2006): 328

29. Francis CW, Pellegrini VD Jr, Totterman S, Boyd AD Jr, Marder VJ, Liebert KM, Stulberg BN, Ayers DC, Rosenberg A, Kessler C, Johanson NA "Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin." J Bone Joint Surg Am 79 (1997): 1365-72

30. Luzzatto G, Cordiano I, Patrassi G, Fabris F "Heparin-induced thrombocytopenia: discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use." Thromb Haemost 75 (1996): 211-2

31. Wallentin L, Swahn E, Kontny F, Husted S, Lagerqvist B, Stahle E, Nielsen JD, Dellborg M, Geiran O, Grande P, Hulting J, KystMa "Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study." Lancet 354 (1999): 701-7

32. Foo SY, Everett BM, Yeh RW, et al. "Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization." Am Heart J 152 (2006): 290.e1-7

33. Reeves JH, Cumming AR, Gallagher L, OBrien JL, Santamaria JD "A controlled trial of low-molecular-weight heparin (Dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration." Crit Care Med 27 (1999): 2224-8

34. Peters FPJ, Doevendans PAFM, Erdkamp FLG, Vanderent FWC, Deheer F "Low molecular weight heparin-induced thrombocytopenia and thrombosis." Eur J Haematol 56 (1996): 329-30

35. Baroletti SA, Goldhaber SZ "Heparin-induced thrombocytopenia." Circulation 114 (2006): e355-6

36. Begelman SM, Hursting MJ, Aghababian RV, McCollum D "Heparin-induced thrombocytopenia from venous thromboembolism treatment." J Intern Med 258 (2005): 563-72

37. Arnold DM, Kelton JG "Heparin-induced thrombocytopenia: an iceberg rising." Mayo Clin Proc 80 (2005): 988-90

38. Dang CH, Durkalski VL, Nappi JM "Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia." Pharmacotherapy 26 (2006): 461-8

39. Selleng K, Warkentin TE, Greinacher A "Heparin-induced thrombocytopenia in intensive care patients." Crit Care Med 35 (2007): 1165-76

40. Balestra B, Quadri P, Biasiutti FD, Furlan M, Lammle B "Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites." Eur J Haematol 53 (1994): 61-3

41. Laposata M, Green D, VanCott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC "College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban." Arch Pathol Lab Med 122 (1998): 799-807

42. Warkentin TE "Drug-induced immune-mediated thrombocytopenia--from purpura to thrombosis." N Engl J Med 356 (2007): 891-3

43. Porras MC, Bonilla BC, Gomez EP, Ruiz MG "Dalteparin-induced extremity hematoma complicated by probable compartment syndrome." Ann Pharmacother 35 (2001): 643-4

44. Prandoni P, Siragusa S, Girolami B, Fabris F "The incidence of heparin-induced thrombocytopenia in medical patients treated with low molecular weight heparin." Blood 106 (2005): 3049-54

45. Caen JP "A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the preventin of deep vein thrombosis in general surgery." Thromb Haemost 59 (1988): 216-20

46. Manoharan A "Heparin-induced skin reaction with low molecular-weight heparin ." Eur J Haematol 48 (1992): 234

47. Moreau A, Dompmartin A, Esnault P, Michel M, Leroy D "Delayed hypersensitivity at the injection sites of a low-molecular-weight heparin." Contact Dermatitis 34 (1996): 31-4

48. Ojeda E, Perez MC, Mataix R, Arbelo A, Jimenez S, Campo C, Balda I "Skin necrosis with a low molecular weight heparin." Br J Haematol 82 (1992): 620

49. Ueda A, Nagase S, Morito N, Yotsumoto M, Ohba S, Hasegawa Y, Narita M, Koyama A "Anaphylactoid reaction induced by low-molecular-weight heparin in a hemodialysis patient." Nephron 87 (2001): 93-4

50. Melissari E, Sas S, Kanthou C, Pemberton KD, Kakkar VV "The use of LMW heparin in treating thromboembolism during pregnancy and prevention of osteoporosis." Thromb Haemost 65 (1991): 926

51. Sivakumaran M, Ghosh K, Zaidi Y, Hutchinson RM "Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient." Clin Lab Haematol 18 (1996): 55-7

52. Apsner R, Horl WH, SunderPlassmann G "Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation." Blood 97 (2001): 2914-5

53. Komericki P, Grims R, Kranke B, Aberer W "Acute generalized exanthematous pustulosis from dalteparin." J Am Acad Dermatol 57 (2007): 718-21

54. Barnes C, Deidun D, Hynes K, Monagle P "Alopecia and dalteparin: a previously unreported association." Blood 96 (2000): 1618-9

55. Lin PH, Bush RL, Lumsden AB "Low molecular weight heparin induced priapism." J Urol 172 (2004): 263

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.